Analysis of ANC recovery from a Phase III study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

被引：0
|
作者：
Bondarenko, I. [1 ]
Bias, P. [2 ]
Elsaesser, R. [2 ]
Buchner, A. [2 ]
机构：
[1] Dnepropetrovsk Municipal Clin Hosp 4, Dnepropetrovsk, Ukraine
[2] Teva Ratiopharm, Ulm, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1961
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [1] A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel
    Gladkov, Oleg
    Moiseyenko, Vladimir
    Bondarenko, Igor N.
    Shparyk, Yaroslav
    Barash, Steve
    Adar, Liat
    Avisar, Noa
    ONCOLOGIST, 2016, 21 (01): : 7 - 15
  • [2] IMMUNOGENICITY OF LIPEGFILGRASTIM AND PEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: INTEGRATED ANALYSIS FROM PHASE II AND III STUDIES
    Abdolzade-Bavil, A.
    Zou, L.
    Sadhu, C.
    Buchner, A.
    Liu, P.
    HAEMATOLOGICA, 2013, 98 : 421 - 421
  • [3] Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
    Igor Bondarenko
    Oleg A Gladkov
    Reiner Elsaesser
    Anton Buchner
    Peter Bias
    BMC Cancer, 13
  • [4] Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
    Bondarenko, Igor
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    BMC CANCER, 2013, 13
  • [5] Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study
    Gladkov, Oleg A.
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    Elsaesser, Reiner
    SUPPORTIVE CARE IN CANCER, 2016, 24 (01) : 395 - 400
  • [6] CHEMOTHERAPY-ASSOCIATED TREATMENT BURDEN IN BREAST CANCER PATIENTS RECEIVING LIPEGFILGRASTIM OR PEGFILGRASTIM: SECONDARY EFFICACY DATA FROM A PHASE III STUDY
    Gladkov, O.
    Buchner, A.
    Bias, P.
    Mueller, U.
    Elsaesser, R.
    HAEMATOLOGICA, 2013, 98 : 426 - 426
  • [7] Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study
    Oleg A. Gladkov
    Anton Buchner
    Peter Bias
    Udo Müller
    Reiner Elsässer
    Supportive Care in Cancer, 2016, 24 : 395 - 400
  • [8] EFFICACY AND SAFETY OF LIPEGFILGRASTIM COMPARED WITH PEGFILGRASTIM IN PATIENTS WITH BREAST CANCER WHO ARE RECEIVING CHEMOTHERAPY
    Udo, M.
    Bondarenko, I.
    Gladkov, O.
    Elaesser, R.
    Buchner, A.
    Bias, P.
    HAEMATOLOGICA, 2012, 97 : 553 - 553
  • [9] ABSOLUTE NEUTROPHIL COUNTS IN A STUDY OF LIPEGFILGRASTIM COMPARED WITH PEGFILGRASTIM IN PATIENTS WITH BREAST CANCER WHO ARE RECEIVING CHEMOTHERAPY
    Gladkov, O. A.
    Bondarenko, I. M.
    Elsaesser, R.
    Buchner, A.
    Bias, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 500 - 500
  • [10] Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.
    Bondarenko, Igor
    Gladkov, Oleg
    Elaesser, Reiner
    Buchner, Anton
    Bias, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345